Halo-quinoline compounds treat lymphomas and leukemia
Summary
The European Patent Office published patent EP3735407A1 granting protection for substituted halo-quinoline derivatives developed by INSERM, Université Côte d'Azur, CNRS, and CHU Nice. The compounds are specifically claimed for treating lymphomas and leukemia (A61P 35/00 classification). The patent covers 31 designated contracting states including major European markets.
What changed
The EPO published patent application EP3735407A1 for substituted halo-quinoline derivatives as therapeutic agents for lymphomas and leukemia. The patent names five inventors and lists four co-applicants: INSERM, Université Côte d'Azur, CNRS, and CHU Nice. The international patent classification includes C07D 215/44 (quinoline compounds), A61K 31/4706 (therapeutic preparations), and A61P 35/00 (antineoplastic agents).
For pharmaceutical and biotechnology companies developing oncology therapies, this patent represents potential blocking IP in the hematologic cancer space. Research institutions and drug developers should conduct freedom-to-operate analyses before pursuing similar compound classes. The designated states cover 31 European countries including Germany, France, UK, Italy, and Spain, providing broad territorial protection for the claimed invention.
What to do next
- Monitor patent portfolio for freedom-to-operate implications
- Review compound claims for licensing opportunities
- Assess therapeutic applications in oncology pipeline
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SUBSTITUTED HALO-QUINOLINE DERIVATES FOR USE IN THE TREATMENT OF LYMPHOMAS AND LEUKEMIA
Publication EP3735407A1 Kind: A1 Apr 01, 2026
Applicants
INSTITUT NATIONAL DE LA SANTE ET DE LA
RECHERCHE MEDICALE - INSERM, UNIVERSITÉ CÔTE D'AZUR, Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Nice
Inventors
PASSERON, Thierry, BENHIDA, Rachid, DAO, Pascal, DE DONATIS, Gian Marco, MARTIN, Anthony, VERHOEYEN, Els
IPC Classifications
C07D 215/44 20060101AFI20190712BHEP A61K 31/4706 20060101ALI20190712BHEP A61P 35/00 20060101ALI20190712BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.